Diplomat Pharmacy, Inc. (NYSE: DPLO), is expanding its strategic relationship with medication adherence company SMRxT, creator of the Nomi® system.
FLINT, Mich., April 25, 2019 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), is expanding its strategic relationship with medication adherence company SMRxT, creator of the Nomi® system. Nomi sensor technologies record when a patient takes their medication, including the number of tablets. Real-time reporting gives healthcare providers the insight to manage patient adherence challenges. Diplomat is now integrating data from Nomi into its end-to-end pharmacy operating system. This will enable a more fully integrated approach to medication adherence and patient engagement. “We saw an opportunity to expand our patient care model by adding technology,” said Gary Rice, Diplomat’s executive vice president of operations. “Our continuing integration of systems and technology helps us as we work to fill gaps in care for patients. Taking care of patients has always been the center of our mission.” With the Nomi system, pharmacies know a patient’s precise dosing behavior and can contact them right away to resolve adherence barriers, such as side effects that deter them from continuing therapy. “We’re excited to expand our business relationship with Diplomat,” said Michael Huffer, RPh, president and CEO of SMRxT. “This new data integration should help Diplomat provide the right care for each patient in even more tailored and efficient ways.” To learn more about Diplomat, visit diplomat.is. About Diplomat About Nomi CONTACT: Gary Rice, RPh, MS, MBA, CSP View original content to download multimedia:http://www.prnewswire.com/news-releases/diplomat-using-smrxt-technology-to-enhance-patient-care-300838687.html SOURCE Diplomat Pharmacy, Inc. | ||
Company Codes: NYSE:DPLO |